ARGX vs VRTX
argenx SE and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $115B against $56B. On trailing earnings VRTX is the cheaper of the two at a P/E of 29.7 against 42.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year VRTX returned +32% against +12% for ARGX. The RyuScore puts VRTX ahead, 59 against 11 out of 100.
| Figure | ARGX | VRTX |
|---|---|---|
| Last close | $825 | $510 |
| Market cap | $56B | $115B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 42.2 | 29.7 |
| 1-year return | +12% | +32% |
| 5-year return | +156% | +168% |
| RyuScoresector-relative, 1–10 | 11/100 | 59/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 75% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.